Gene · 5686
PSMA5: proteasome 20S subunit alpha 5
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PSMA5: proteasome 20S subunit alpha 5. Genes, record 5686. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5686
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P28066 | Proteasome subunit alpha type-5 | 241 | 177 | Ensembl, GeneID, HGNC |
Source UniProt
Patents21
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59514 | P28066 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 2766 | P28066 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 2766 | P28066 | Espacenet |
| WO 2024240908 A1 | 2024-11-28 | 28 | P28066 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67876 | P28066 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 170847 | P28066 | Espacenet |
| EP 3647788 A1 | 2020-05-06 | 21 | P28066 | Espacenet |
| WO 2020043864 A1 | 2020-03-05 | 1953 | P28066 | Espacenet |
| KR 1020200020927 A | 2020-02-26 | 21 | P28066 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 239949 | P28066 | Espacenet |
1 to 10 of 21
See all 21 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| BORTEZOMIB D-MANNITOL | CHEMBL5315122 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| CARFILZOMIB | CHEMBL451887 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB | CHEMBL2141296 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB CITRATE | CHEMBL3545432 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| MARIZOMIB | CHEMBL371405 | 20S proteasome inhibitor | INHIBITOR | ChEMBL |
| OPROZOMIB | CHEMBL2103884 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
Trials1,241
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | CARFILZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07513129 | BORTEZOMIB | PHASE1 | ClinicalTrials.gov | |
| NCT07479979 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07464210 | BORTEZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463807 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07428369 | BORTEZOMIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | BORTEZOMIB | PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | CARFILZOMIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,241
See all 1,241 trialsNIH grants555
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PSMA5 papers | Newest fiscal year |
|---|---|---|---|
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 7 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 2 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016520 | Abramson Cancer Center Support Grant | 2 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 2 | 2025 |
| ZICES102445 | Gene Expression and Microarrays | 2 | 2025 |
| K12EY022299 | Michigan Vision Clinician Scientist Development Program | 1 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 1 | 2025 |
| P01CA229086 | The impact of changes in chromatin architecture on cancer phenotypes and tumor progression | 1 | 2025 |
| P20GM103475 | Advancing Competitive Biomedical Research in Puerto Rico | 1 | 2025 |
1 to 10 of 555Source NIH's project files
See all 555 nih grantsPapers689
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PSMA1, PSMA5, and PSMB2 serve as prognostic biomarkers and are correlated with tumor-infiltrating leukocytes in HCC. | Epigenetics | 2026 | 42735232 | PubTator, text mining | PubMed |
| Exosomal gene-based predictive model and therapeutic target identification for Alzheimer's disease: A bioinformatics analysis. | PLoS One | 2026 | 42475384 | PubTator, text mining | PubMed |
| Sarcomatoid Renal Cell Carcinoma: Biological Features and Therapeutic Implications-A Narrative Review. | Curr Urol Rep | 2026 | 41792526 | PubTator, text mining | PubMed |
| Ubiquitin-proteasome system dysregulation in FAM111B-related poikiloderma and phenotypic spectrum expansion: new case reports and long-term follow-up. | EBioMedicine | 2025 | 40840166 | PubTator, text mining | PubMed |
| Development and validation of G2M signature-based prognostic model for stratifying colon cancer prognosis. | Discov Oncol | 2025 | 40783878 | PubTator, text mining | PubMed |
| PSMA5 as a modulator of glioblastoma senescence and prognosis. | BMC Cancer | 2025 | 40597008 | PubTator, text mining | PubMed |
| Brain and blood transcriptome-wide association studies identify five novel genes associated with Alzheimer's disease. | J Alzheimers Dis | 2025 | 40111921 | PubTator, text mining | PubMed |
| Are cities under bright lights more innovative? Evidence from China. | Heliyon | 2024 | 39253158 | PubTator, text mining | PubMed |
| Unveiling the role of PSMA5 in glioma progression and prognosis. | Discov Oncol | 2024 | 39240463 | PubTator, text mining | PubMed |
| Role and mechanism of IRF9 in promoting the progression of rheumatoid arthritis by regulating macrophage polarization via PSMA5. | Heliyon | 2024 | 39170377 | PubTator, text mining | PubMed |
1 to 10 of 689
See all 689 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5686
GET https://conductscience.org/api/genes/v1/5686/patents?page=2